Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Hazard ratios (HR) for breast cancer-specific and overall mortality by chemotherapy use in patients aged ≤ 70 years old with the RS 26–30

From: Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30

  Breast cancer-specific mortality Overall mortality
No/unknown chemotherapy
(Reference)
Yes chemotherapy
[HR (95% CI)]
No/unknown chemotherapy
(Reference)
Yes chemotherapy
[HR (95% CI)]
2004–2015 dataset (n = 5290)
 No. of events 58 62 117 98
 Age-adjusted model 1.00 0.76 (0.53 to 1.09) 1.00 0.63 (0.48 to 0.83)
 Age- and clinicopathological factor-adjusted model 1.00 0.66 (0.45 to 0.95) 1.00 0.56 (0.42 to 0.74)
 Age- and clinicopathological and treatment factor-adjusted model 1.00 0.68 (0.47 to 0.99) 1.00 0.58 (0.44 to 0.76)
2010–2015 dataset (n = 3540)
 No. of events 22 23 40 40
 Age-adjusted model 1.00 0.73 (0.40 to 1.32) 1.00 0.75 (0.48 to 1.18)
 Age- and clinicopathological factor-adjusted model 1.00 0.63 (0.34 to 1.15) 1.00 0.67 (0.43 to 1.05)
 Age- and clinicopathological and treatment factor-adjusted model 1.00 0.64 (0.35 to 1.18) 1.00 0.72 (0.45 to 1.14)
2004–2009 dataset (n = 1750)
 No. of events 36 39 77 58
 Age-adjusted model 1.00 0.77 (0.49 to 1.23) 1.00 0.56 (0.40 to 0.79)
 Age- and clinicopathological factor-adjusted model 1.00 0.68 (0.43 to 1.09) 1.00 0.50 (0.35 to 0.71)
 Age- and clinicopathological and treatment factor-adjusted model 1.00 0.71 (0.44 to 1.13) 1.00 0.51 (0.36 to 0.72)
  1. Age at diagnosis is used by categorization into ≤ 50, 51–60, and 61–70 years. Adjusted clinicopathological factors are year of diagnosis (2004–2005, 2006–2007, 2008–2009 in 2004–2009 dataset and 2010–2011, 2012–2013, and 2014–2015 in 2010–2015 dataset), race/ethnicity (White, Black, and other), history of cancer (no and yes), marital status (married and single/other), histologic type (ductal, lobular, and mixed ductal-lobular/other), tumor stage (T1b, T1c, and T2–3), grade (I, II, III, and missing), and ER/PR status (both ER/PR-positive and either ER/PR-positive). Treatment factors are type of surgery (breast-conservation surgery and mastectomy) and radiation therapy (no/unknown and yes)
  2. RS recurrence score, HR hazard ratio, CI confidence interval, No. number